Payment overview · 2025
General Payments
$60,182.69
234 reported records · 38 companies
Healthcare provider profile · identity verified
Douglas S. Stuart, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ATLANTA, GA · NPI 1548251572
Verified facts
What the public records show
CMS Open Payments records show Douglas S. Stuart, M.D. received $60,182.69 in general payments during 2025 across 234 reported records.
TG Therapeutics, Inc. accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Qulipta, Tysabri, Ultomiris, Vumerity, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Soliris by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ULTOMIRIS as an associated drug or biological on 24281 records involving 10608 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ultomiris by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zeposia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 976 records involving 466 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zeposia by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33,124.60 | 55.0% | 43 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15,961.45 | 26.5% | 24 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $7,448.75 | 12.4% | 8 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $616.88 | 1.0% | 41 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $381.86 | 0.6% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $306.75 | 0.5% | 18 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $262.44 | 0.4% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $257.91 | 0.4% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $249.45 | 0.4% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $151.09 | 0.2% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.75 | 0.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $114.24 | 0.2% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $102.39 | 0.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $96.28 | 0.2% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $87.30 | 0.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.48 | 0.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.07 | 0.1% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $69.92 | 0.1% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.87 | 0.1% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $57.23 | 0.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.19 | 0.1% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $49.05 | 0.1% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $43.05 | 0.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.46 | 0.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $38.97 | 0.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $38.40 | 0.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$33.99 | 0.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.32 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $32.05 | 0.1% | 2 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $27.19 | 0.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.66 | 0.0% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $22.51 | 0.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $21.84 | 0.0% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.42 | 0.0% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $19.70 | 0.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $18.49 | 0.0% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.99 | 0.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.70 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,217.50 | 16 |
| Food and Beverage | $5,909.82 | 204 |
| Consulting Fee | $5,619.63 | 2 |
| Travel and Lodging | $2,435.74 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $33,124.60 | 43 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $7,599.84 | 11 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $6,537.82 | 14 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $306.75 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $294.30 | 13 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $216.20 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $210.71 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $210.71 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $169.05 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $168.52 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $167.71 | 9 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $125.75 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $102.39 | 5 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $90.70 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $88.86 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $85.48 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $69.92 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $68.12 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $66.87 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $57.23 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $49.05 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $43.05 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $38.40 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $33.32 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $32.05 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.25 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ULTOMIRIS ultomiris |
2025 | Ultomiris | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ULTOMIRIS open payments reported associated product |
CMS Open Payments — General Payments 24281 supporting records · 10608 recipient NPIs · example record 1202912926 |
Ultomiris · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
93 | 11 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 976 supporting records · 466 recipient NPIs · example record 1184381876 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 606 | 161 |
| Clonazepam | Clonazepam | 478 | 88 |
| Baclofen | Baclofen | 385 | 112 |
| Donepezil Hcl | Donepezil Hcl | 384 | 113 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 376 | 68 |
| Dimethyl Fumarate | Dimethyl Fumarate | 274 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 264 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 243 | 45 |
| Alprazolam | Alprazolam | 213 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 197 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 44 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 186 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 30 |
| Prednisone | Prednisone | 169 | 90 |
| Pregabalin | Pregabalin | 160 | 32 |
| Methylphenidate Hcl | Methylphenidate Hcl | 155 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 31 |
| Trazodone Hcl | Trazodone Hcl | 143 | 39 |
| Lamotrigine | Lamotrigine | 136 | 34 |
| Tramadol Hcl | Tramadol Hcl | 122 | 27 |
| Levetiracetam | Levetiracetam | 121 | 34 |
| Dalfampridine Er | Dalfampridine | 117 | 27 |
| Propranolol Hcl | Propranolol Hcl | 114 | 30 |
| Memantine Hcl | Memantine Hcl | 111 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 30 |
| Bupropion Xl | Bupropion Hcl | 107 | 29 |
| Modafinil | Modafinil | 104 | 39 |
| Sertraline Hcl | Sertraline Hcl | 96 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 93 | 13 |
| Tecfidera | Dimethyl Fumarate | 93 | 11 |
| Diazepam | Diazepam | 90 | 21 |
| Topiramate | Topiramate | 85 | 30 |
| Carisoprodol | Carisoprodol | 84 | 14 |
| Lorazepam | Lorazepam | 82 | 23 |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 81 | suppressed |
| Carbamazepine | Carbamazepine | 81 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 80 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 72 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 69 | 21 |
| Meloxicam | Meloxicam | 67 | 13 |
| Temazepam | Temazepam | 67 | 12 |
| Kesimpta Pen | Ofatumumab | 64 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 17 |
| Aripiprazole | Aripiprazole | 60 | 14 |
| Eszopiclone | Eszopiclone | 60 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 18 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 57 | 12 |
| Mirtazapine | Mirtazapine | 57 | 17 |
| Oxcarbazepine | Oxcarbazepine | 57 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 50 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 13 |
| Primidone | Primidone | 44 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Fentanyl | Fentanyl | 40 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 39 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 38 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 37 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Rivastigmine | Rivastigmine | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Omeprazole | Omeprazole | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 11 |
| Risperidone | Risperidone | 27 | suppressed |
| Ultomiris | Ravulizumab-Cwvz | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 11 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 25 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Glatopa | Glatiramer Acetate | 23 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 23 | 11 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Teriflunomide | Teriflunomide | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Lisinopril | Lisinopril | 19 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 18 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Fingolimod | Fingolimod Hcl | 17 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Soliris | Eculizumab | 15 | suppressed |
| Vumerity | Diroximel Fumarate | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 13 | suppressed |
| Tysabri | Natalizumab | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $60,182.69 · 234 records | TG Therapeutics, Inc. | AMPYRA, AUSTEDO XR, BOTOX, BRIUMVI, CREXONT, Dysport, FYCOMPA, Fintepla, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PANZYGA, PEMGARDA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Radicava, Sunosi, Symbravo, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WAKIX, Xeomin, ZAVZPRET, ZEPOSIA, Zilbrysq | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error